Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
In this international study involving 809 patients with HIV and TB coinfection, earlier therapy for both infections, versus waiting 8 to 12 weeks to initiate antiretrovirals after anti-TB therapy, was beneficial in patients with a low CD4+ T-cell count (<50 per cubic millimeter). The treatment of...
Uloženo v:
| Vydáno v: | The New England journal of medicine Ročník 365; číslo 16; s. 1482 - 1491 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Waltham, MA
Massachusetts Medical Society
20.10.2011
|
| Témata: | |
| ISSN: | 0028-4793, 1533-4406, 1533-4406 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | In this international study involving 809 patients with HIV and TB coinfection, earlier therapy for both infections, versus waiting 8 to 12 weeks to initiate antiretrovirals after anti-TB therapy, was beneficial in patients with a low CD4+ T-cell count (<50 per cubic millimeter).
The treatment of patients with tuberculosis and newly identified infection with human immunodeficiency virus type 1 (HIV-1) is one of the most challenging aspects of HIV medicine. Antiretroviral therapy (ART) must be started during treatment for tuberculosis,
1
,
2
yet starting ART very early in the course of tuberculosis therapy increases the pill burden, the potential drug toxicity, and the risk of tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS).
3
,
4
For these reasons, programs, providers, and patients are reluctant to initiate ART during the intensive 8-week induction phase of tuberculosis therapy, when the pill burden and toxicity of tuberculosis medications are greatest. . . . |
|---|---|
| AbstractList | BackgroundAntiretroviral therapy (ART) is indicated during tuberculosis treatment in patients infected with human immunodeficiency virus type 1 (HIV-1), but the timing for the initiation of ART when tuberculosis is diagnosed in patients with various levels of immune compromise is not known.MethodsWe conducted an open-label, randomized study comparing earlier ART (within 2 weeks after the initiation of treatment for tuberculosis) with later ART (between 8 and 12 weeks after the initiation of treatment for tuberculosis) in HIV-1 infected patients with CD4+ T-cell counts of less than 250 per cubic millimeter and suspected tuberculosis. The primary end point was the proportion of patients who survived and did not have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)–defining illness at 48 weeks.ResultsA total of 809 patients with a median baseline CD4+ T-cell count of 77 per cubic millimeter and an HIV-1 RNA level of 5.43 log10 copies per milliliter were enrolled. In the earlier-ART group, 12.9% of patients had a new AIDS-defining illness or died by 48 weeks, as compared with 16.1% in the later-ART group (95% confidence interval [CI], −1.8 to 8.1; P=0.45). Among patients with screening CD4+ T-cell counts of less than 50 per cubic millimeter, 15.5% of patients in the earlier-ART group versus 26.6% in the later-ART group had a new AIDS-defining illness or died (95% CI, 1.5 to 20.5; P=0.02). Tuberculosis-associated immune reconstitution inflammatory syndrome was more common with earlier ART than with later ART (11% vs. 5%, P=0.002). The rate of viral suppression at 48 weeks was 74% and did not differ between the groups (P=0.38).ConclusionsOverall, earlier ART did not reduce the rate of new AIDS-defining illness and death, as compared with later ART. In persons with CD4+ T-cell counts of less than 50 per cubic millimeter, earlier ART was associated with a lower rate of new AIDS-defining illnesses and death. (Funded by the National Institutes of Health and others; ACTG A5221 ClinicalTrials.gov number, NCT00108862.) In this international study involving 809 patients with HIV and TB coinfection, earlier therapy for both infections, versus waiting 8 to 12 weeks to initiate antiretrovirals after anti-TB therapy, was beneficial in patients with a low CD4+ T-cell count (<50 per cubic millimeter). The treatment of patients with tuberculosis and newly identified infection with human immunodeficiency virus type 1 (HIV-1) is one of the most challenging aspects of HIV medicine. Antiretroviral therapy (ART) must be started during treatment for tuberculosis, 1 , 2 yet starting ART very early in the course of tuberculosis therapy increases the pill burden, the potential drug toxicity, and the risk of tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS). 3 , 4 For these reasons, programs, providers, and patients are reluctant to initiate ART during the intensive 8-week induction phase of tuberculosis therapy, when the pill burden and toxicity of tuberculosis medications are greatest. . . . Antiretroviral therapy (ART) is indicated during tuberculosis treatment in patients infected with human immunodeficiency virus type 1 (HIV-1), but the timing for the initiation of ART when tuberculosis is diagnosed in patients with various levels of immune compromise is not known. We conducted an open-label, randomized study comparing earlier ART (within 2 weeks after the initiation of treatment for tuberculosis) with later ART (between 8 and 12 weeks after the initiation of treatment for tuberculosis) in HIV-1 infected patients with CD4+ T-cell counts of less than 250 per cubic millimeter and suspected tuberculosis. The primary end point was the proportion of patients who survived and did not have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)-defining illness at 48 weeks. A total of 809 patients with a median baseline CD4+ T-cell count of 77 per cubic millimeter and an HIV-1 RNA level of 5.43 log(10) copies per milliliter were enrolled. In the earlier-ART group, 12.9% of patients had a new AIDS-defining illness or died by 48 weeks, as compared with 16.1% in the later-ART group (95% confidence interval [CI], -1.8 to 8.1; P=0.45). Among patients with screening CD4+ T-cell counts of less than 50 per cubic millimeter, 15.5% of patients in the earlier-ART group versus 26.6% in the later-ART group had a new AIDS-defining illness or died (95% CI, 1.5 to 20.5; P=0.02). Tuberculosis-associated immune reconstitution inflammatory syndrome was more common with earlier ART than with later ART (11% vs. 5%, P=0.002). The rate of viral suppression at 48 weeks was 74% and did not differ between the groups (P=0.38). Overall, earlier ART did not reduce the rate of new AIDS-defining illness and death, as compared with later ART. In persons with CD4+ T-cell counts of less than 50 per cubic millimeter, earlier ART was associated with a lower rate of new AIDS-defining illnesses and death. (Funded by the National Institutes of Health and others; ACTG A5221 ClinicalTrials.gov number, NCT00108862.). Antiretroviral therapy (ART) is indicated during tuberculosis treatment in patients infected with human immunodeficiency virus type 1 (HIV-1), but the timing for the initiation of ART when tuberculosis is diagnosed in patients with various levels of immune compromise is not known.BACKGROUNDAntiretroviral therapy (ART) is indicated during tuberculosis treatment in patients infected with human immunodeficiency virus type 1 (HIV-1), but the timing for the initiation of ART when tuberculosis is diagnosed in patients with various levels of immune compromise is not known.We conducted an open-label, randomized study comparing earlier ART (within 2 weeks after the initiation of treatment for tuberculosis) with later ART (between 8 and 12 weeks after the initiation of treatment for tuberculosis) in HIV-1 infected patients with CD4+ T-cell counts of less than 250 per cubic millimeter and suspected tuberculosis. The primary end point was the proportion of patients who survived and did not have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)-defining illness at 48 weeks.METHODSWe conducted an open-label, randomized study comparing earlier ART (within 2 weeks after the initiation of treatment for tuberculosis) with later ART (between 8 and 12 weeks after the initiation of treatment for tuberculosis) in HIV-1 infected patients with CD4+ T-cell counts of less than 250 per cubic millimeter and suspected tuberculosis. The primary end point was the proportion of patients who survived and did not have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)-defining illness at 48 weeks.A total of 809 patients with a median baseline CD4+ T-cell count of 77 per cubic millimeter and an HIV-1 RNA level of 5.43 log(10) copies per milliliter were enrolled. In the earlier-ART group, 12.9% of patients had a new AIDS-defining illness or died by 48 weeks, as compared with 16.1% in the later-ART group (95% confidence interval [CI], -1.8 to 8.1; P=0.45). Among patients with screening CD4+ T-cell counts of less than 50 per cubic millimeter, 15.5% of patients in the earlier-ART group versus 26.6% in the later-ART group had a new AIDS-defining illness or died (95% CI, 1.5 to 20.5; P=0.02). Tuberculosis-associated immune reconstitution inflammatory syndrome was more common with earlier ART than with later ART (11% vs. 5%, P=0.002). The rate of viral suppression at 48 weeks was 74% and did not differ between the groups (P=0.38).RESULTSA total of 809 patients with a median baseline CD4+ T-cell count of 77 per cubic millimeter and an HIV-1 RNA level of 5.43 log(10) copies per milliliter were enrolled. In the earlier-ART group, 12.9% of patients had a new AIDS-defining illness or died by 48 weeks, as compared with 16.1% in the later-ART group (95% confidence interval [CI], -1.8 to 8.1; P=0.45). Among patients with screening CD4+ T-cell counts of less than 50 per cubic millimeter, 15.5% of patients in the earlier-ART group versus 26.6% in the later-ART group had a new AIDS-defining illness or died (95% CI, 1.5 to 20.5; P=0.02). Tuberculosis-associated immune reconstitution inflammatory syndrome was more common with earlier ART than with later ART (11% vs. 5%, P=0.002). The rate of viral suppression at 48 weeks was 74% and did not differ between the groups (P=0.38).Overall, earlier ART did not reduce the rate of new AIDS-defining illness and death, as compared with later ART. In persons with CD4+ T-cell counts of less than 50 per cubic millimeter, earlier ART was associated with a lower rate of new AIDS-defining illnesses and death. (Funded by the National Institutes of Health and others; ACTG A5221 ClinicalTrials.gov number, NCT00108862.).CONCLUSIONSOverall, earlier ART did not reduce the rate of new AIDS-defining illness and death, as compared with later ART. In persons with CD4+ T-cell counts of less than 50 per cubic millimeter, earlier ART was associated with a lower rate of new AIDS-defining illnesses and death. (Funded by the National Institutes of Health and others; ACTG A5221 ClinicalTrials.gov number, NCT00108862.). |
| Author | Havlir, Diane V Sawe, Fred Kendall, Michelle A Ive, Prudence Kumarasamy, N Kumwenda, Johnstone Hosseinipour, Mina C Mohapi, Lerato Sanchez, Jorge Veloso, Valdilea G Wu, Xingye Sanchez, Alejandro Moko, Evans Hogg, Evelyn Rooney, James F Padayatchi, Nesri Lama, Javier R Luetkemeyer, Anne F Swindells, Susan Mugyenyi, Peter Sanne, Ian Lalloo, Umesh Andersen, Janet Pape, Jean W Santos, Breno R Hakim, James Some, Fatuma F Asmelash, Aida Qasba, Sarojini S Reid, Stewart |
| Author_xml | – sequence: 1 givenname: Diane V surname: Havlir fullname: Havlir, Diane V – sequence: 2 givenname: Michelle A surname: Kendall fullname: Kendall, Michelle A – sequence: 3 givenname: Prudence surname: Ive fullname: Ive, Prudence – sequence: 4 givenname: Johnstone surname: Kumwenda fullname: Kumwenda, Johnstone – sequence: 5 givenname: Susan surname: Swindells fullname: Swindells, Susan – sequence: 6 givenname: Sarojini S surname: Qasba fullname: Qasba, Sarojini S – sequence: 7 givenname: Anne F surname: Luetkemeyer fullname: Luetkemeyer, Anne F – sequence: 8 givenname: Evelyn surname: Hogg fullname: Hogg, Evelyn – sequence: 9 givenname: James F surname: Rooney fullname: Rooney, James F – sequence: 10 givenname: Xingye surname: Wu fullname: Wu, Xingye – sequence: 11 givenname: Mina C surname: Hosseinipour fullname: Hosseinipour, Mina C – sequence: 12 givenname: Umesh surname: Lalloo fullname: Lalloo, Umesh – sequence: 13 givenname: Valdilea G surname: Veloso fullname: Veloso, Valdilea G – sequence: 14 givenname: Fatuma F surname: Some fullname: Some, Fatuma F – sequence: 15 givenname: N surname: Kumarasamy fullname: Kumarasamy, N – sequence: 16 givenname: Nesri surname: Padayatchi fullname: Padayatchi, Nesri – sequence: 17 givenname: Breno R surname: Santos fullname: Santos, Breno R – sequence: 18 givenname: Stewart surname: Reid fullname: Reid, Stewart – sequence: 19 givenname: James surname: Hakim fullname: Hakim, James – sequence: 20 givenname: Lerato surname: Mohapi fullname: Mohapi, Lerato – sequence: 21 givenname: Peter surname: Mugyenyi fullname: Mugyenyi, Peter – sequence: 22 givenname: Alejandro surname: Sanchez fullname: Sanchez, Alejandro – sequence: 22 givenname: Jorge surname: Sanchez fullname: Sanchez, Jorge – sequence: 23 givenname: Javier R surname: Lama fullname: Lama, Javier R – sequence: 24 givenname: Jean W surname: Pape fullname: Pape, Jean W – sequence: 26 givenname: Aida surname: Asmelash fullname: Asmelash, Aida – sequence: 27 givenname: Evans surname: Moko fullname: Moko, Evans – sequence: 28 givenname: Fred surname: Sawe fullname: Sawe, Fred – sequence: 29 givenname: Janet surname: Andersen fullname: Andersen, Janet – sequence: 30 givenname: Ian surname: Sanne fullname: Sanne, Ian |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24623407$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22010914$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc1PGzEQxa2KqoS0x16rVaWK0xZ_e32phFCAVNBe0l4txzsLjnbt1N5F4r-vI0IpSPgyh_nN85s3R-ggxAAIfST4K8FCnvxYfL-OlmDCJFZv0IwIxmrOsTxAM4xpU3Ol2SE6ynmDyyNcv0OHlGKCNeEztFj5wYebKnbVaRh9gjHFO59sX61uIdntfdXFVF0uf9ekWoYO3OhjqGxoq9W0huSmPmaf36O3ne0zfNjXOfp1vlidXdZXPy-WZ6dXtRNMj7XQwFWrKCNk3YAEBVi3gvG27VTXYgVCU3AcKFXKQluartEYd4KuG6YkY3P07UF3O60HaB2EsVg12-QHm-5NtN487wR_a27inWGMql1Gc3S8F0jxzwR5NIPPDvreBohTNuU3yYgQTSE_vyA3cUqhbGcaraVUkuMCffrfzz8jj_kW4MsesNnZvks2OJ-fOC4p41gVjj1wLsWcE3TG-dHusi5r-N4QbHbXNs-uXabqF1OPwq_xezfDkE2AzfAK9xclOLUq |
| CODEN | NEJMAG |
| CitedBy_id | crossref_primary_10_1016_j_tube_2013_01_001 crossref_primary_10_1186_s12981_016_0106_y crossref_primary_10_1002_eji_201343632 crossref_primary_10_1007_s13546_013_0700_4 crossref_primary_10_1097_QAI_0000000000000060 crossref_primary_10_1371_journal_pone_0192991 crossref_primary_10_1007_s15010_013_0504_1 crossref_primary_10_1016_j_mpmed_2013_05_015 crossref_primary_10_1016_S0140_6736_20_31316_7 crossref_primary_10_1097_QAI_0000000000001833 crossref_primary_10_7861_clinmedicine_13_6_s24 crossref_primary_10_1371_journal_pone_0089861 crossref_primary_10_1056_NEJMoa1013911 crossref_primary_10_1016_j_cell_2013_09_045 crossref_primary_10_1258_ijsa_2012_012090 crossref_primary_10_1186_1741_7015_11_253 crossref_primary_10_1186_s12879_016_1375_8 crossref_primary_10_2217_fvl_12_76 crossref_primary_10_1111_tmi_12110 crossref_primary_10_1007_s11940_018_0490_9 crossref_primary_10_1111_imr_12063 crossref_primary_10_1177_0885066618803871 crossref_primary_10_1016_S0140_6736_15_00319_0 crossref_primary_10_1097_QCO_0000000000000090 crossref_primary_10_1155_2011_513967 crossref_primary_10_1186_s12981_015_0053_z crossref_primary_10_1016_j_cct_2019_105846 crossref_primary_10_1186_1471_2334_14_S1_S5 crossref_primary_10_1186_2050_6511_15_61 crossref_primary_10_1016_j_ijid_2015_09_002 crossref_primary_10_1093_trstmh_trx023 crossref_primary_10_1371_journal_pone_0266082 crossref_primary_10_1016_j_ccm_2013_01_011 crossref_primary_10_1371_journal_pone_0083643 crossref_primary_10_1111_odi_12606 crossref_primary_10_1016_S2352_3018_17_30167_4 crossref_primary_10_1093_cid_ciz560 crossref_primary_10_1128_AAC_00191_13 crossref_primary_10_1111_biom_12780 crossref_primary_10_1007_s11910_017_0796_0 crossref_primary_10_1093_cid_ciy590 crossref_primary_10_1097_QAD_0000000000001941 crossref_primary_10_1097_QAI_0000000000000970 crossref_primary_10_1371_journal_pone_0090614 crossref_primary_10_1093_aje_kwu338 crossref_primary_10_2174_1574893613666180621153734 crossref_primary_10_1007_s11904_015_0256_x crossref_primary_10_1097_01_aids_0000434936_57880_cd crossref_primary_10_1186_s12879_016_1916_1 crossref_primary_10_1186_s12981_025_00738_4 crossref_primary_10_1186_s43058_023_00464_w crossref_primary_10_7448_IAS_19_1_21002 crossref_primary_10_1016_j_lpm_2017_01_017 crossref_primary_10_1371_journal_pone_0158262 crossref_primary_10_1186_s40794_020_00113_3 crossref_primary_10_1007_s11904_014_0213_0 crossref_primary_10_1371_journal_pone_0153921 crossref_primary_10_1016_S2352_3018_25_00040_2 crossref_primary_10_1093_bmb_ldv003 crossref_primary_10_1371_journal_pone_0157725 crossref_primary_10_1080_01621459_2015_1093947 crossref_primary_10_1111_2049_632X_12108 crossref_primary_10_1111_hiv_12256 crossref_primary_10_1002_jia2_25772 crossref_primary_10_1371_journal_pone_0126591 crossref_primary_10_1177_0956462419881074 crossref_primary_10_1093_jac_dku376 crossref_primary_10_3109_00365548_2013_878033 crossref_primary_10_1186_s12879_017_2700_6 crossref_primary_10_1016_S2352_3018_19_30189_4 crossref_primary_10_1038_nrdp_2016_76 crossref_primary_10_2217_fvl_12_123 crossref_primary_10_1080_14740338_2020_1694901 crossref_primary_10_1136_bmjopen_2024_087218 crossref_primary_10_1093_cid_ciy016 crossref_primary_10_1097_QAI_0000000000000030 crossref_primary_10_1097_QAI_0000000000000151 crossref_primary_10_1016_j_amsu_2020_05_004 crossref_primary_10_1111_resp_12120 crossref_primary_10_1093_cid_cit246 crossref_primary_10_1097_QAI_0000000000000037 crossref_primary_10_1186_s12981_016_0128_5 crossref_primary_10_3402_gha_v9_31543 crossref_primary_10_1097_MCP_0b013e32835f27f8 crossref_primary_10_1097_QAI_0000000000000032 crossref_primary_10_1097_QAI_0b013e318251aeb4 crossref_primary_10_1128_microbiolspec_TNMI7_0028_2016 crossref_primary_10_1007_s10461_013_0595_9 crossref_primary_10_1016_j_cct_2020_105938 crossref_primary_10_1128_AAC_03073_14 crossref_primary_10_1097_COH_0000000000000197 crossref_primary_10_1111_resp_12156 crossref_primary_10_1093_cid_cit019 crossref_primary_10_1111_j_1468_1293_2012_01029_9_x crossref_primary_10_1186_s12879_018_3037_5 crossref_primary_10_1111_myc_12977 crossref_primary_10_1097_EDE_0000000000000923 crossref_primary_10_1586_14787210_2015_1029917 crossref_primary_10_1183_09031936_00138712 crossref_primary_10_1080_17441692_2014_988164 crossref_primary_10_2471_BLT_12_111153 crossref_primary_10_1056_NEJMcpc1005311 crossref_primary_10_1097_01_qai_0000434954_65620_f3 crossref_primary_10_1016_S1473_3099_20_30869_0 crossref_primary_10_1097_QAI_0000000000000944 crossref_primary_10_1371_journal_pone_0240159 crossref_primary_10_1128_AAC_03332_14 crossref_primary_10_1371_journal_pone_0112017 crossref_primary_10_2217_fvl_12_18 crossref_primary_10_1136_bcr_2017_221775 crossref_primary_10_1183_09031936_00200210 crossref_primary_10_1097_INF_0b013e3182940e0a crossref_primary_10_1007_s11908_013_0378_5 crossref_primary_10_1016_S0140_6736_19_31882_3 crossref_primary_10_1016_j_jinf_2017_01_016 crossref_primary_10_1016_S2352_3018_15_00252_0 crossref_primary_10_3851_IMP2701 crossref_primary_10_1186_s12981_016_0118_7 crossref_primary_10_1177_0956462412472431 crossref_primary_10_2217_fvl_15_91 crossref_primary_10_1186_s12879_015_1275_3 crossref_primary_10_1155_2012_238012 crossref_primary_10_1007_s11904_012_0126_8 crossref_primary_10_1586_1744666X_2014_892828 crossref_primary_10_12688_wellcomeopenres_16473_1 crossref_primary_10_1186_s12879_018_3392_2 crossref_primary_10_3201_eid1903_120998 crossref_primary_10_1097_COH_0b013e328354bd44 crossref_primary_10_1016_S1473_3099_13_70187_7 crossref_primary_10_1097_01_aids_0000432456_14099_c7 crossref_primary_10_1371_journal_pone_0077697 crossref_primary_10_1186_s12879_018_3077_x crossref_primary_10_3390_tropicalmed5010041 crossref_primary_10_1016_S1473_3099_14_70739_X crossref_primary_10_1016_S2213_2600_14_70031_1 crossref_primary_10_1097_QAI_0b013e318246538f crossref_primary_10_1371_journal_pone_0084866 crossref_primary_10_1016_j_cmi_2016_10_008 crossref_primary_10_1093_jac_dku348 crossref_primary_10_1038_nrd4001 crossref_primary_10_1093_infdis_jiu600 crossref_primary_10_7448_IAS_19_1_20504 crossref_primary_10_1097_QAI_0000000000000247 crossref_primary_10_1371_journal_pone_0127645 crossref_primary_10_1097_QAD_0000000000000546 crossref_primary_10_1371_journal_pone_0087584 crossref_primary_10_1093_cid_ciz256 crossref_primary_10_1007_s40506_018_0145_0 crossref_primary_10_1371_journal_pone_0078073 crossref_primary_10_1371_journal_pone_0074057 crossref_primary_10_1016_j_aohep_2019_09_008 crossref_primary_10_1016_j_eimc_2013_04_009 crossref_primary_10_1093_cid_cis630 crossref_primary_10_1186_s12913_014_0627_9 crossref_primary_10_1371_journal_pone_0047370 crossref_primary_10_1111_hiv_13025 crossref_primary_10_1177_09564624251369565 crossref_primary_10_3390_v16040494 crossref_primary_10_1016_j_ccm_2019_07_006 crossref_primary_10_1056_NEJMoa1312884 crossref_primary_10_1093_cid_ciab097 crossref_primary_10_1097_QCO_0b013e328352b664 crossref_primary_10_2217_fvl_2019_0012 crossref_primary_10_1164_rccm_201909_1874ST crossref_primary_10_1111_biom_13530 crossref_primary_10_1056_NEJMc1113986 crossref_primary_10_1097_QAD_0000000000000311 crossref_primary_10_1371_journal_pone_0156602 crossref_primary_10_1093_jac_dkac079 crossref_primary_10_1111_hiv_13016 crossref_primary_10_1186_s12879_023_08897_3 crossref_primary_10_1186_1472_6963_13_397 crossref_primary_10_1186_s12879_017_2473_y crossref_primary_10_1093_ofid_ofy063 crossref_primary_10_1055_a_1934_8303 crossref_primary_10_1177_2325957415599210 crossref_primary_10_1016_S2222_1808_15_61023_4 crossref_primary_10_1371_journal_pone_0048599 crossref_primary_10_3389_fimmu_2025_1594107 crossref_primary_10_1093_cid_civ477 crossref_primary_10_1016_j_ijid_2019_04_015 crossref_primary_10_1016_S1473_3099_13_70328_1 crossref_primary_10_1136_bmj_m216 crossref_primary_10_1371_journal_pone_0196831 crossref_primary_10_1111_hiv_13727 crossref_primary_10_1186_1471_2334_13_292 crossref_primary_10_1371_journal_pone_0040623 crossref_primary_10_1128_microbiolspec_TNMI7_0008_2016 crossref_primary_10_3389_fphar_2017_00689 crossref_primary_10_1097_QAI_0b013e31829f6df2 crossref_primary_10_1097_QCO_0b013e32835ba8f9 crossref_primary_10_1016_S1473_3099_14_71051_5 crossref_primary_10_1016_j_banm_2023_07_007 crossref_primary_10_1080_23744235_2017_1404633 crossref_primary_10_1016_S1473_3099_14_70711_X crossref_primary_10_1097_QCO_0000000000000704 crossref_primary_10_22625_2072_6732_2025_17_3_97_105 crossref_primary_10_1038_nrmicro2712 crossref_primary_10_1093_ofid_ofy075 crossref_primary_10_1016_S1473_3099_13_70015_X crossref_primary_10_1111_hiv_12073 crossref_primary_10_4103_ijmy_ijmy_101_19 crossref_primary_10_1016_j_tube_2019_101863 crossref_primary_10_1093_cid_cis899 crossref_primary_10_1371_journal_pone_0236933 crossref_primary_10_1007_s11908_012_0308_y crossref_primary_10_1177_0956462413486457 crossref_primary_10_1016_j_jiph_2023_10_011 crossref_primary_10_1016_j_eimce_2018_04_009 crossref_primary_10_1111_hiv_12748 crossref_primary_10_1093_cid_cis409 crossref_primary_10_1097_MCP_0b013e32835213d3 crossref_primary_10_1007_s11904_012_0140_x crossref_primary_10_1371_journal_pone_0222650 crossref_primary_10_1097_MD_0000000000007219 crossref_primary_10_1186_1471_2458_14_183 crossref_primary_10_1371_journal_pone_0269765 crossref_primary_10_1016_j_antiviral_2013_12_007 crossref_primary_10_1007_s00393_011_0858_7 crossref_primary_10_1080_14656566_2018_1515916 crossref_primary_10_1016_j_cam_2016_02_051 crossref_primary_10_1111_j_1440_1843_2012_02257_x crossref_primary_10_1016_S1473_3099_25_00364_0 crossref_primary_10_1371_journal_pone_0142873 crossref_primary_10_1080_19466315_2024_2388520 crossref_primary_10_1093_cid_ciz732 crossref_primary_10_1093_cid_cix1125 crossref_primary_10_1097_QAI_0b013e31825cfe8e crossref_primary_10_1097_QAI_0000000000000201 crossref_primary_10_1056_NEJMe1109546 crossref_primary_10_1186_1471_2334_14_304 crossref_primary_10_1016_j_ccm_2013_02_004 crossref_primary_10_1093_cid_ciu283 crossref_primary_10_1016_j_ccm_2013_02_003 crossref_primary_10_1097_QAD_0000000000001796 crossref_primary_10_1371_journal_pone_0054145 crossref_primary_10_4103_ijmr_IJMR_660_19 crossref_primary_10_1056_NEJMra1200894 crossref_primary_10_1155_2022_9542756 crossref_primary_10_1172_JCI153090 crossref_primary_10_1056_NEJMoa1014181 crossref_primary_10_1371_journal_pone_0138603 crossref_primary_10_1097_COH_0000000000000380 crossref_primary_10_1097_QAI_0b013e3182893fb4 crossref_primary_10_33393_grhta_2025_3292 crossref_primary_10_1371_journal_pone_0274549 crossref_primary_10_1093_cid_cis797 crossref_primary_10_1186_s12879_014_0735_5 crossref_primary_10_2217_fmb_15_9 crossref_primary_10_1513_AnnalsATS_201902_185CME crossref_primary_10_1016_S0140_6736_12_60727_2 crossref_primary_10_1080_17512433_2024_2317954 crossref_primary_10_1097_QAI_0000000000000673 crossref_primary_10_1007_s11908_012_0311_3 crossref_primary_10_1016_S1473_3099_14_70733_9 crossref_primary_10_1097_QAI_0000000000003024 crossref_primary_10_1517_17425255_2014_895813 crossref_primary_10_1016_j_ijid_2017_01_023 crossref_primary_10_1016_S1473_3099_15_70008_3 crossref_primary_10_1016_S2352_3018_23_00081_4 crossref_primary_10_1371_journal_pone_0081538 crossref_primary_10_1093_cid_civ155 crossref_primary_10_1007_s11908_011_0230_8 crossref_primary_10_1007_s00281_015_0532_2 crossref_primary_10_1016_S1473_3099_20_30937_3 crossref_primary_10_1097_QAD_0b013e3283635232 crossref_primary_10_1111_j_1469_0691_2012_03991_x crossref_primary_10_1038_nrneurol_2017_120 crossref_primary_10_1093_trstmh_trx073 crossref_primary_10_1016_S0140_6736_12_61814_5 crossref_primary_10_1093_cid_cit654 crossref_primary_10_1093_cid_ciz877 crossref_primary_10_1186_s12981_019_0250_2 crossref_primary_10_1371_journal_pone_0063541 crossref_primary_10_1177_875512251302900208 crossref_primary_10_1097_QAD_0000000000001333 crossref_primary_10_1097_QAI_0b013e3182410503 crossref_primary_10_1177_003335491412900211 crossref_primary_10_1371_journal_pmed_1002358 crossref_primary_10_1371_journal_pone_0149372 crossref_primary_10_1097_INF_0b013e31827031aa crossref_primary_10_1186_s12879_021_06533_6 crossref_primary_10_1513_AnnalsATS_201909_694CME crossref_primary_10_3389_fpubh_2021_623468 crossref_primary_10_1097_COH_0000000000000241 crossref_primary_10_1016_S0140_6736_15_01092_2 crossref_primary_10_1186_1742_6405_10_19 crossref_primary_10_1371_journal_pone_0049492 crossref_primary_10_1093_cid_ciw376 crossref_primary_10_1002_phar_1921 crossref_primary_10_1093_ofid_ofae035 crossref_primary_10_1097_QAD_0b013e3283565dd1 crossref_primary_10_1016_j_clinthera_2024_04_002 crossref_primary_10_1080_17512433_2017_1259066 crossref_primary_10_1089_aid_2012_0192 crossref_primary_10_1002_jia2_25423 crossref_primary_10_1093_infdis_jit102 crossref_primary_10_1016_S2352_3018_14_70027_X crossref_primary_10_1007_s40262_014_0144_3 crossref_primary_10_1111_hiv_12426 crossref_primary_10_1097_COH_0000000000000009 crossref_primary_10_1111_hir_12230 crossref_primary_10_1371_journal_pone_0188235 crossref_primary_10_1371_journal_pone_0073250 crossref_primary_10_3201_eid2612_202245 crossref_primary_10_1093_cid_civ978 crossref_primary_10_1016_j_idc_2014_05_004 crossref_primary_10_1371_journal_pone_0049140 crossref_primary_10_1183_09031936_00188313 crossref_primary_10_1016_j_idc_2014_05_002 crossref_primary_10_3402_gha_v7_23105 crossref_primary_10_1186_s12879_016_1933_0 crossref_primary_10_1371_journal_pone_0084585 crossref_primary_10_1097_QAI_0b013e318276cda9 crossref_primary_10_1016_j_ccc_2013_03_010 crossref_primary_10_1371_journal_pone_0210327 crossref_primary_10_1016_j_jinf_2017_10_007 crossref_primary_10_1097_QAI_0000000000000763 crossref_primary_10_1007_s15006_014_3119_2 crossref_primary_10_1016_j_idc_2019_05_002 crossref_primary_10_1097_QAD_0000000000001239 crossref_primary_10_7448_IAS_17_1_19034 crossref_primary_10_1016_j_idc_2019_05_005 crossref_primary_10_1186_1471_2334_12_66 crossref_primary_10_1016_j_ogc_2016_07_009 crossref_primary_10_1111_hiv_12217 crossref_primary_10_1016_j_revmed_2024_01_008 crossref_primary_10_4102_sajhivmed_v16i1_346 crossref_primary_10_1111_odi_12389 crossref_primary_10_1093_jac_dkv384 crossref_primary_10_1016_S2213_2600_17_30079_6 crossref_primary_10_1016_j_trsl_2015_07_010 crossref_primary_10_1002_phar_1388 crossref_primary_10_1093_infdis_jis034 crossref_primary_10_1371_journal_pone_0122587 crossref_primary_10_7861_clinmedicine_14_3_279 crossref_primary_10_1186_s13012_017_0661_1 crossref_primary_10_1016_S2352_3018_16_30090_X crossref_primary_10_1371_journal_pone_0083270 crossref_primary_10_1371_journal_pone_0207859 crossref_primary_10_1016_S2213_2600_15_00063_6 crossref_primary_10_1111_hiv_12201 crossref_primary_10_1111_hiv_12119_9 |
| Cites_doi | 10.1086/651497 10.2307/2281868 10.1056/NEJMoa1014181 10.1097/QAD.0b013e32833dfc68 10.1371/journal.pone.0005575 10.1056/NEJMoa0905848 10.1086/651492 10.2307/2336502 10.1093/cid/cir230 10.2307/2530245 10.1086/651495 10.1016/j.ccm.2009.08.016 10.1056/NEJMoa1013911 10.1016/S1473-3099(08)70184-1 10.1001/jama.300.4.423 10.1016/S0140-6736(10)60492-8 10.1136/thx.2003.019224 |
| ContentType | Journal Article |
| Contributor | Parker, Robert Firnhaber, Cindy John, Melanie-Ann Walawander, Ann Anthony, Patricia Pfister, Sabina Mensah-King, Martha Barlow, Naz Purcelle, Eva Komarow, Lauren Hanekom, Willem Martinez, Ana Corbett, Amanda Kondo, Pualani Gutzman, Howard Zolopa, Andrew Behm, Travis Shaw, Audrey Jones, Lynne van der Horst, Charles Poblenz, Marianne Supparatpinyo, Khuanchai Smith, Beverly Alston Sprenger, Heather Appiah, Kuku DeCarlo, Ellen Salata, Robert Campos, Pablo Asmuth, David Mahgoub, Siham Aweeka, Fran Martinson, Francis Near, Karen Hunter, Harold Nicotera, Janet Leger, Paul Suckow, Carol |
| Contributor_xml | – sequence: 1 givenname: Lynne surname: Jones fullname: Jones, Lynne – sequence: 2 givenname: Carol surname: Suckow fullname: Suckow, Carol – sequence: 3 givenname: Ana surname: Martinez fullname: Martinez, Ana – sequence: 4 givenname: Janet surname: Nicotera fullname: Nicotera, Janet – sequence: 5 givenname: Martha surname: Mensah-King fullname: Mensah-King, Martha – sequence: 6 givenname: Patricia surname: Anthony fullname: Anthony, Patricia – sequence: 7 givenname: Fran surname: Aweeka fullname: Aweeka, Fran – sequence: 8 givenname: Naz surname: Barlow fullname: Barlow, Naz – sequence: 9 givenname: Travis surname: Behm fullname: Behm, Travis – sequence: 10 givenname: Pablo surname: Campos fullname: Campos, Pablo – sequence: 11 givenname: Cindy surname: Firnhaber fullname: Firnhaber, Cindy – sequence: 12 givenname: Khuanchai surname: Supparatpinyo fullname: Supparatpinyo, Khuanchai – sequence: 13 givenname: Paul surname: Leger fullname: Leger, Paul – sequence: 14 givenname: Francis surname: Martinson fullname: Martinson, Francis – sequence: 15 givenname: Robert surname: Salata fullname: Salata, Robert – sequence: 16 givenname: Andrew surname: Zolopa fullname: Zolopa, Andrew – sequence: 17 givenname: Eva surname: Purcelle fullname: Purcelle, Eva – sequence: 18 givenname: Beverly Alston surname: Smith fullname: Smith, Beverly Alston – sequence: 19 givenname: Karen surname: Near fullname: Near, Karen – sequence: 20 givenname: Ellen surname: DeCarlo fullname: DeCarlo, Ellen – sequence: 21 givenname: Siham surname: Mahgoub fullname: Mahgoub, Siham – sequence: 22 givenname: Robert surname: Parker fullname: Parker, Robert – sequence: 23 givenname: Lauren surname: Komarow fullname: Komarow, Lauren – sequence: 24 givenname: David surname: Asmuth fullname: Asmuth, David – sequence: 25 givenname: Willem surname: Hanekom fullname: Hanekom, Willem – sequence: 26 givenname: Ann surname: Walawander fullname: Walawander, Ann – sequence: 27 givenname: Amanda surname: Corbett fullname: Corbett, Amanda – sequence: 28 givenname: Melanie-Ann surname: John fullname: John, Melanie-Ann – sequence: 29 givenname: Charles surname: van der Horst fullname: van der Horst, Charles – sequence: 30 givenname: Pualani surname: Kondo fullname: Kondo, Pualani – sequence: 31 givenname: Howard surname: Gutzman fullname: Gutzman, Howard – sequence: 32 givenname: Harold surname: Hunter fullname: Hunter, Harold – sequence: 33 givenname: Sabina surname: Pfister fullname: Pfister, Sabina – sequence: 34 givenname: Marianne surname: Poblenz fullname: Poblenz, Marianne – sequence: 35 givenname: Audrey surname: Shaw fullname: Shaw, Audrey – sequence: 36 givenname: Heather surname: Sprenger fullname: Sprenger, Heather – sequence: 37 givenname: Kuku surname: Appiah fullname: Appiah, Kuku |
| Copyright | Copyright © 2011 Massachusetts Medical Society. All rights reserved. 2015 INIST-CNRS |
| Copyright_xml | – notice: Copyright © 2011 Massachusetts Medical Society. All rights reserved. – notice: 2015 INIST-CNRS |
| CorporateAuthor | AIDS Clinical Trials Group Study A5221 |
| CorporateAuthor_xml | – name: AIDS Clinical Trials Group Study A5221 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM |
| DOI | 10.1056/NEJMoa1013607 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials - QC Biological Science Collection eLibrary ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Premium Collection New England Journal of Medicine Biological Sciences Consumer Health Database (ProQuest) Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Psychology MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| EndPage | 1491 |
| ExternalDocumentID | PMC3327101 2491072141 22010914 24623407 10_1056_NEJMoa1013607 NJ201110203651607 |
| Genre | Original Article Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States--US San Francisco California |
| GeographicLocations_xml | – name: San Francisco California – name: United States--US |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: AI38838 – fundername: PHS HHS grantid: 5U01A1069417-04 – fundername: PHS HHS grantid: A169426 – fundername: NIAID NIH HHS grantid: U01 AI038858 – fundername: NIAID NIH HHS grantid: AI 69432 – fundername: PHS HHS grantid: 5U01A1066453-04 – fundername: PHS HHS grantid: U01A1068636 – fundername: PHS HHS grantid: A1069428 – fundername: NIAID NIH HHS grantid: U01 AI038855 – fundername: PHS HHS grantid: U01 A169414-03 – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: U01 AI038855-04 || AI – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: U01 AI068636-01 || AI – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: U01 AI038858-04 || AI – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: U01 AI068634-01 || AI |
| GroupedDBID | - 0R 0WA 123 186 1AW 1KJ 1VV 29N 2KS 2WC 34G 39C 3O- 3V. 4 4.4 53G 55 5D0 5RE 68V 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI 8RP AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AASXA AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQES ABQIJ ABUFD ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACRZS ACVYA ADBBV ADCBC AENEX AETEA AFDAS AFFNX AFHKK AFKRA AGNAY AHMBA AHVBC AIKQT AJJEV AJYGW ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCR BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS EJD ET EX3 F20 F5P FD8 FM. FYUFA G8K GJ GNUQQ GUQSH H13 HCIFZ HZ IH2 K-O K78 KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC MVM N9A NEJ O0- O9- OK1 OMK OVD P-O P2P PADUT PCD PEA PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TN5 TWZ U1N UCV UKR UMD UQL VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZKB ZR0 ZXP --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 1CY 36B 6TJ AAMNW AAYXX ABBLC ABCQX ABDPE ABDQB ABJNI ACKOT ACPFK ADRHT ADUKH ADXHL AERZD AFFHD AGHSJ BYPQX CCPQU CITATION HF~ HMCUK HZ~ N4W NAPCQ PHGZM PHGZT PJZUB PPXIY PQGLB PSYQQ TEORI TUQ UKHRP YFH YR2 YR5 YYP ZCA ZVN ~KM 41~ 8WZ 9M8 A6W AAQOH AAUTI ABEFU ACPVT ACTDY AFFDN AFOSN AJUXI ALIPV D0S FA8 IQODW J5H LPU MQT NHB OHT QZG SKT UBX WHG XOL YHZ YQI YQJ YYQ ZGI CGR CUY CVF ECM EIF NPM 7XB BEC K0Y PKEHL Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c539t-59e47d72311b8e6e7e09d534ddf7fd07e592ec4e2277aed09dc8900f52b837633 |
| IEDL.DBID | DCD |
| ISICitedReferencesCount | 436 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000296009500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Tue Nov 04 02:00:51 EST 2025 Sun Nov 09 09:55:27 EST 2025 Sun Nov 02 17:48:17 EST 2025 Mon Jul 21 06:03:14 EDT 2025 Mon Jul 21 09:16:13 EDT 2025 Tue Nov 18 22:40:35 EST 2025 Sat Nov 29 03:54:28 EST 2025 Wed Nov 11 00:31:23 EST 2020 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 16 |
| Keywords | Immunopathology Antiretroviral agent HIV-1 virus Retroviridae AIDS Mycobacterial infection Immune deficiency Lentivirus Infection Virus Medicine Chemotherapy Treatment Tuberculosis Viral disease Bacteriosis Temporal study Antiviral Human immunodeficiency virus Timing |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c539t-59e47d72311b8e6e7e09d534ddf7fd07e592ec4e2277aed09dc8900f52b837633 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 Authors’ full names and degrees, along with members of the A5221 study team, are listed in the Supplementary Appendix |
| OpenAccessLink | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1013607?articleTools=true |
| PMID | 22010914 |
| PQID | 899667640 |
| PQPubID | 40644 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3327101 proquest_miscellaneous_900631558 proquest_journals_899667640 pubmed_primary_22010914 pascalfrancis_primary_24623407 crossref_citationtrail_10_1056_NEJMoa1013607 crossref_primary_10_1056_NEJMoa1013607 mms_nejm_10_1056_NEJMoa1013607 |
| ProviderPackageCode | DCD 7FN |
| PublicationCentury | 2000 |
| PublicationDate | 2011-10-20 |
| PublicationDateYYYYMMDD | 2011-10-20 |
| PublicationDate_xml | – month: 10 year: 2011 text: 2011-10-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | Waltham, MA |
| PublicationPlace_xml | – name: Waltham, MA – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2011 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | Sterling, TR, Pham, PA, Chaisson, RE (r001) 2010; 50 Lan, KKG, DeMets, DL (r012) 1983; 70 Zolopa, A, Andersen, J, Powderly, W (r016) 2009; 4 Getahun, H, Gunneberg, C, Granich, R, Nunn, P (r019) 2010; 50 Kalbfleisch J, Prentice R. The statistical analysis of failure time data. New York: John Wiley, 1980. Dheda, K, Shean, K, Zumla, A (r017) 2010; 375 Kaplan, E, Meier, P (r009) 1958; 53 Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 2004. ( .) Pai, M, Minion, J, Sohn, H, Zwerling, A, Perkins, MD (r006) 2009; 30 O'Brien, PC, Fleming, TR (r011) 1979; 35 Meintjes, G, Lawn, SD, Scano, F (r008) 2008; 8 Breen, RA, Smith, CJ, Bettinson, H (r003) 2004; 59 Abdool Karim, SS, Naidoo, K, Grobler, A (r014) 2011; 365 Havlir, DV, Getahun, H, Sanne, I, Nunn, P (r020) 2008; 300 Abdool Karim, SS, Naidoo, K, Grobler, A (r002) 2010; 362 Meintjes, G, Wilkinson, RJ, Morroni, C (r015) 2010; 24 Torok, ME, Yen, NT, Chau, TT (r018) 2011; 52 Global tuberculosis control: a short update to the 2009 report. Geneva: World Health Organization, 2009. ( .) Burman, W, Weis, S, Vernon, A (r004) 2007; 11 Blanc, F-X, Sok, T, Laureillard, D (r013) 2011; 365 Howard, AA, El-Sadr, WM (r021) 2010; 50 Burman W (r004) 2007; 11 r020 r010 r021 r011 r001 r012 r006 r017 r018 r008 r019 r009 r002 r013 r003 r014 r005 r016 Meintjes G (r015) 2010; 24 22010921 - N Engl J Med. 2011 Oct 20;365(16):1538-40. doi: 10.1056/NEJMe1109546. 22296084 - N Engl J Med. 2012 Feb 2;366(5):474; author reply 475-6. doi: 10.1056/NEJMc1113986. |
| References_xml | – volume: 362 start-page: 697 year: 2010 end-page: 706 ident: r002 article-title: Timing of initiation of antiretroviral drugs during tuberculosis therapy. publication-title: N Engl J Med – volume: 8 start-page: 516 year: 2008 end-page: 523 ident: r008 article-title: Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. publication-title: Lancet Infect Dis – reference: Global tuberculosis control: a short update to the 2009 report. Geneva: World Health Organization, 2009. ( .) – volume: 35 start-page: 549 year: 1979 end-page: 556 ident: r011 article-title: A multiple testing procedure for clinical trials. publication-title: Biometrics – volume: 365 start-page: 1492 year: 2011 end-page: 1501 ident: r014 article-title: Integration of antiretroviral therapy with tuberculosis treatment. publication-title: N Engl J Med – volume: 24 start-page: 2381 year: 2010 end-page: 2390 ident: r015 article-title: Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. publication-title: AIDS – volume: 59 start-page: 704 year: 2004 end-page: 707 ident: r003 article-title: Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. publication-title: Thorax – volume: 52 start-page: 1374 year: 2011 end-page: 1383 ident: r018 article-title: Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. publication-title: Clin Infect Dis – volume: 300 start-page: 423 year: 2008 end-page: 430 ident: r020 article-title: Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. publication-title: JAMA – volume: 30 start-page: 701 year: 2009 end-page: 716 ident: r006 article-title: Novel and improved technologies for tuberculosis diagnosis: progress and challenges. publication-title: Clin Chest Med – volume: 375 start-page: 1798 year: 2010 end-page: 1807 ident: r017 article-title: Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. publication-title: Lancet – reference: Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 2004. ( .) – reference: Kalbfleisch J, Prentice R. The statistical analysis of failure time data. New York: John Wiley, 1980. – volume: 50 start-page: S223 year: 2010 end-page: S230 ident: r001 article-title: HIV infection-related tuberculosis: clinical manifestations and treatment. publication-title: Clin Infect Dis – volume: 53 start-page: 457 year: 1958 end-page: 481 ident: r009 article-title: Nonparametric estimation of incomplete observations. publication-title: J Am Stat Assoc – volume: 4 start-page: e5575 year: 2009 end-page: e5575 ident: r016 article-title: Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. publication-title: PLoS One – volume: 50 start-page: S201 year: 2010 end-page: S207 ident: r019 article-title: HIV infection-associated tuberculosis: the epidemiology and the response. publication-title: Clin Infect Dis – volume: 365 start-page: 1471 year: 2011 end-page: 1481 ident: r013 article-title: Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. publication-title: N Engl J Med – volume: 70 start-page: 659 year: 1983 end-page: 663 ident: r012 article-title: Discrete sequential boundaries for clinical trials. publication-title: Biometrika – volume: 11 start-page: 1282 year: 2007 end-page: 1289 ident: r004 article-title: Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. publication-title: Int J Tuberc Lung Dis – volume: 50 start-page: S238 year: 2010 end-page: S244 ident: r021 article-title: Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned. publication-title: Clin Infect Dis – ident: r021 doi: 10.1086/651497 – ident: r010 – ident: r009 doi: 10.2307/2281868 – ident: r014 doi: 10.1056/NEJMoa1014181 – volume: 24 start-page: 2381 year: 2010 ident: r015 publication-title: AIDS doi: 10.1097/QAD.0b013e32833dfc68 – ident: r016 doi: 10.1371/journal.pone.0005575 – ident: r002 doi: 10.1056/NEJMoa0905848 – ident: r019 doi: 10.1086/651492 – ident: r005 – ident: r012 doi: 10.2307/2336502 – ident: r018 doi: 10.1093/cid/cir230 – ident: r011 doi: 10.2307/2530245 – volume: 11 start-page: 1282 year: 2007 ident: r004 publication-title: Int J Tuberc Lung Dis – ident: r001 doi: 10.1086/651495 – ident: r006 doi: 10.1016/j.ccm.2009.08.016 – ident: r013 doi: 10.1056/NEJMoa1013911 – ident: r008 doi: 10.1016/S1473-3099(08)70184-1 – ident: r020 doi: 10.1001/jama.300.4.423 – ident: r017 doi: 10.1016/S0140-6736(10)60492-8 – ident: r003 doi: 10.1136/thx.2003.019224 – reference: 22296084 - N Engl J Med. 2012 Feb 2;366(5):474; author reply 475-6. doi: 10.1056/NEJMc1113986. – reference: 22010921 - N Engl J Med. 2011 Oct 20;365(16):1538-40. doi: 10.1056/NEJMe1109546. |
| SSID | ssj0000149 |
| Score | 2.5628731 |
| Snippet | In this international study involving 809 patients with HIV and TB coinfection, earlier therapy for both infections, versus waiting 8 to 12 weeks to initiate... Antiretroviral therapy (ART) is indicated during tuberculosis treatment in patients infected with human immunodeficiency virus type 1 (HIV-1), but the timing... BackgroundAntiretroviral therapy (ART) is indicated during tuberculosis treatment in patients infected with human immunodeficiency virus type 1 (HIV-1), but... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref mms |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1482 |
| SubjectTerms | Acquired immune deficiency syndrome Adult AIDS AIDS-Related Opportunistic Infections - drug therapy Anti-Retroviral Agents - administration & dosage Anti-Retroviral Agents - adverse effects Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral drugs Antiretroviral therapy Antitubercular Agents - therapeutic use Antiviral agents Biological and medical sciences CD4 antigen CD4 Lymphocyte Count Drug Administration Schedule Female General aspects HIV HIV Infections - complications HIV Infections - drug therapy HIV Infections - mortality HIV-1 Human immunodeficiency virus Human viral diseases Humans Immune reconstitution Infectious diseases Inflammation Kaplan-Meier Estimate Laboratories Lymphocytes T Male Medical sciences Mortality Patients Pharmacology. Drug treatments Ribonucleic acid RNA Tuberculosis Tuberculosis - complications Tuberculosis - drug therapy Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
| SummonAdditionalLinks | – databaseName: Science Database dbid: M2P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwELVoQYgL5aslFCofECesJo69jk-oQq1aiVY9LFVvkROPYVHXKZssvx9P4g27FeXC2SPL8djjF_vpPULeawCHwlgs_CobFvCtYNo4ybQwuZNVbk1vB3T1RV1cFNfX-jJyc9pIq1zVxL5Q26bGO_LDAoG5moj00-1PhqZR-LgaHTS2yMMAbDJkdJ3zyzX1qIh-4wVSlNgMR_4hGs03JkPBMjSSXTuStubzFgmSpg1z5AZzi7-hz7skyrVT6WTnP7_nGXka4Sg9GtbPc_IA_Avy-Dw-uL8kx1N0_fpGG0ePfBfKY4dXEGEgdDrIEdAAeunp2RXL6FnkdXlqvKXTZQWLennTtLP2Ffl6cjz9fMqi8wKrZa47JjUIZVXAfllVwAQUpNrKXFjrlLOpAqk51AI4V8qADY11odPUSV4VWLHyXbLtGw-vCQ0Qp-ZCOhWgobCV0WAUGK1tkbuCA0_Ix9Xkl3WUJUd3jJuyfx6Xk3IjVwn5MIbfDnoc9wUehEyWHn7M7w3YSPLYHRcBEgoM2F9lrowbuy3HtCWEjq1hR-Izi_HQLNtSI-wLMK1IyN6wRP50jdwDnYmEqI3FMwag2Pdmi59970W_85wHMJi9-eeg9skTHjmKPH1LtrvFEt6RR_WvbtYuDvrd8Rsr9RWs priority: 102 providerName: ProQuest |
| Title | Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis |
| URI | http://dx.doi.org/10.1056/NEJMoa1013607 https://www.ncbi.nlm.nih.gov/pubmed/22010914 https://www.proquest.com/docview/899667640 https://www.proquest.com/docview/900631558 https://pubmed.ncbi.nlm.nih.gov/PMC3327101 |
| Volume | 365 |
| WOSCitedRecordID | wos000296009500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBGY databaseName: New England Journal of Medicine customDbUrl: eissn: 1533-4406 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: DCD dateStart: 19900101 isFulltext: true titleUrlDefault: https://www.nejm.org/medical-index providerName: Massachusetts Medical Society – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M7P dateStart: 19800103 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database (ProQuest) customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0R dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7X7 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0T dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7RV dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: BENPR dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2M dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 8C1 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2O dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2P dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Pb9MwFLbYhtAu_P4RBpUPiBMRiWPX9nF0nTaJlqoKVW-RE9ujaE2mJuXvxy_xumUwweW7-MVJ7Gfns_3yPYQ-SGMsCGOFbqmsQsdvaSiVZaGkKrEsT7Rq0wEtvvLpVCyXcnYjknT3BJ8NP0NO-ErFoC0Gf40fgI-B-56MTm7pRHme67eKvJjmH5f3Pj5763UNoZCqdq1huzQWf-OZd8Mlb31_Tp_895M_RY89xcTHnU88Qw9M-Rw9mvhD9BdonEImrwtcWXxcNm7Ka2Bbwd0Sp53EAHZEFp-dL8IYn_tYrRKrUuN0m5tNsb2s6lX9En0_Haejs9BnUwgLlsgmZNJQrrnjc3EuzNBwE0nNEqq15VZH3DBJTEENIZwro11hIWQUWUZyAbNQ8grtl1Vp3iDsaEtBKLPc0T2qcyWN4kZJqUViBTEkQJ-umzkrvNQ4ZLy4zNojbzbMek0ToI8786tOY-M-w4Hrs6w0P9f3GvS6c1cdoY7mUTA4uu7fzA_WOhOw5uNDGgUI70rdKIOjE1WaaltnEqico14iQK87Z7ipGuIJZEwDxHtusjMAAe9-Sbn60Qp5JwlxBC9--6_XOkKHxIcekugd2m82W_MePSx-Nat6M0B7fL4AXPIWhUMxigfo4Mt4OpsP2qHicBLNW0wByaTFby3OAPnsN8orCfU |
| linkProvider | Massachusetts Medical Society |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9QwEB21BQEXPguEQvEBOBE1cZx1fECogla76nbVQ6h6C05sw6JuUjZZED-K_4gncZZdRLn1wNkjK46fxy_25D2AF0Jrg8JYvv1Ulr7lt8wX0sS-YDIycR4p2doBnY75ZJKcnYmTDfjZ_wuDZZV9TmwTtaoKPCPfS5CY8wEL3l589dE0Ci9XeweNDhVH-sd3-8VWvxm9t9P7ktLDg_Td0HemAn4RR6LxY6EZV9zSmjBP9EBzHQgVR0wpw40KuI4F1QXTlHIutbKNRSKCwMQ0T3AxRrbfTbjGUFgMKwXpyYpalWPb7sDKSXpairGHxvaVDFEgDY1rV7bAzdmsxoJMWds5MZ2Zxt_Y7p9Fmyu74OGd_-z93YXbjm6T_W593IMNXd6HG8euoOABHKToavaJVIbsl41N_w0esdiBk7STWyCW1JPh6NQPycjVrZVEloqki1zPi8V5VU_rbfhwJYN4CFtlVerHQCyFKyiLDbfUl6lcCi25lkKoJDIJ1dSD1_1kZ4WTXUf3j_Osvf6PB9kaNjx4tQy_6PRGLgvctcjJSv1ldmnAGqiW3VFmKS_DgJ0eKZlLXHW2hIkHZNlqMw5eI8lSV4s6E0hrLQ1NPHjUQfJ311hbIULmAV8D6zIAxczXW8rp51bUPIqoJbvhk38-1HO4OUyPx9l4NDnagVvU1WPS4ClsNfOFfgbXi2_NtJ7vtiuTwMerhvIvHJdyHA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3Pb9MwGP20DTRxGT8HYTB8AE5ETRynjg8ITWzVqm3VhMq0W3BiG4rWZGtaEH8a_x3-Eie0iHHbgbM_WUn8bL84L-8BvBRaGzTG8u2rsvQtv2W-kCb2BZORibNIyToO6OyYj0bJ-bk4XYOf7b8wKKts18R6oVZljmfkvQSJOe-zoGecKuJ0f_Du8srHACn80NqmaTQIOdI_vtu3t-rtcN8O9StKBwfj94e-Cxjw8zgScz8WmnHFLcUJs0T3NdeBUHHElDLcqIDrWFCdM00p51Ir25gnIghMTLMEJ2Zk-12HW5zFFG37T4IPS85Vjnm7wytn72npRg9D7ksZolkahtgubYfr02mF4kxZ2fExTbDG35jvnwLOpR1xcPc_fpb3YMvRcLLXzJv7sKaLB7B54oQGD-FgjGlnn0lpyF4xt9vCHI9e7EMg48aGgViyTw6HZ35Ihk7PVhBZKDJeZHqWLy7KalI9go83chPbsFGUhX4CxFK7nLLYcEuJmcqk0JJrKYRKIpNQTT140w58mjs7dkwFuUhrWUDcT1dw4sHrrvyy8SG5rnDXoigt9NfptQUrAOu6o8xSYYYFOy1qUregVWkHGQ9I12pXIvy8JAtdLqpUIN219DTx4HEDz99do-ZChMwDvgLcrgBNzldbismX2uw8iqglweHTf17UC9i0CE6Ph6OjHbhDnUyTBs9gYz5b6OdwO_82n1Sz3XqSEvh000j-BaAaet8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Timing+of+Antiretroviral+Therapy+for+HIV-1+Infection+and+Tuberculosis&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Havlir%2C+Diane+V&rft.au=Kendall%2C+Michelle+A&rft.au=Ive%2C+Prudence&rft.au=Kumwenda%2C+Johnstone&rft.date=2011-10-20&rft.pub=Massachusetts+Medical+Society&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=365&rft.issue=16&rft.spage=1482&rft.epage=1491&rft_id=info:doi/10.1056%2FNEJMoa1013607&rft.externalDocID=NJ201110203651607 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |